Patents by Inventor Jian Ni

Jian Ni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050186637
    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.
    Type: Application
    Filed: February 10, 2005
    Publication date: August 25, 2005
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig Rosen, Stephen Ullrich
  • Publication number: 20050186616
    Abstract: The invention relates to Cystatin F polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 25, 2005
    Applicant: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Guo-Liang Yu, Reiner Gentz, Jian Ni
  • Publication number: 20050176044
    Abstract: Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions.
    Type: Application
    Filed: January 25, 2005
    Publication date: August 11, 2005
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig Rosen, Reiner Gentz
  • Patent number: 6919078
    Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are antibodies, vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: July 19, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
  • Patent number: 6916786
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 12, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • Patent number: 6916629
    Abstract: The present invention relates to a novel TFPI-3 protein which is a member of the tissue factor protease inhibitor family. In particular, isolated nucleic acid molecules are provided encoding human TFPI-3 proteins. TFPI-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TFPI-3 activity. Also provided are diagnostic methods for detecting hemostasis system-related disorders and therapeutic methods for treating hemostatis system-related disorders.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: July 12, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Tsu-An Hsu, Craig A. Rosen, Jian Ni
  • Patent number: 6908986
    Abstract: Human chemokine Alpha-3 polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: June 21, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Haodong Li, Jeffrey Su
  • Patent number: 6903072
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: June 7, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • Patent number: 6902910
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: June 7, 2005
    Assignees: Human Genome Sciences, Inc., The Regent of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Publication number: 20050118679
    Abstract: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.
    Type: Application
    Filed: November 2, 2004
    Publication date: June 2, 2005
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Steve Ruben, Laurie Brewer, Reiner Gentz, Craig Rosen
  • Publication number: 20050119457
    Abstract: The present invention relates to novel human proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells and recombinant methods for producing the proteins of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 2, 2005
    Applicants: Human Genome Sciences, Inc., Auckland Uniservices, Limited
    Inventors: Jian Ni, Craig Rosen, Reiner Gentz, Jeffrey Su, Geoffrey Krissansen, Ping Feng
  • Publication number: 20050112090
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
    Type: Application
    Filed: August 27, 2003
    Publication date: May 26, 2005
    Inventors: Jian Ni, Craig Rosen, Reiner Gentz
  • Patent number: 6893870
    Abstract: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: May 17, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben, Y. Eric Shi
  • Publication number: 20050089911
    Abstract: The present invention relates to 87 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: October 8, 2004
    Publication date: April 28, 2005
    Inventors: Paul Young, John Greene, Ann Ferrie, Steven Ruben, Craig Rosen, Roxanne Duan, Jing-Shan Hu, Kimberly Florence, Henrik Olsen, Reinhard Ebner, Laurie Brewer, Paul Moore, Yanggu Shi, David LaFleur, Jian Ni
  • Patent number: 6881401
    Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: April 19, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen
  • Patent number: 6878812
    Abstract: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: April 12, 2005
    Assignee: Human Genome Science, Inc.
    Inventors: Jian Ni, Steve Ruben, Laurie Brewer, Reiner Gentz, Craig Rosen
  • Publication number: 20050069943
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: November 3, 2004
    Publication date: March 31, 2005
    Applicant: Human Genome Sciences, Inc.
    Inventors: Roxanne Duan, Steven Ruben, Kimberly Florence, John Greene, Craig Rosen, Paul Young, Ann Ferrie, Guo-Liang Yu, Fouad Janat, Jian Ni, Kenneth Carter, Gregory Endress, Ping Feng, David LaFleur, Yanggu Shi
  • Publication number: 20050069945
    Abstract: Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.
    Type: Application
    Filed: November 23, 2004
    Publication date: March 31, 2005
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Pedro Alfonso, Reiner Gentz, Jeffrey Su
  • Patent number: 6872568
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: March 29, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Patent number: 6861226
    Abstract: The invention relates to hESF I, II and III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: March 1, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz